Journal of Japan Society of Pain Clinicians
Online ISSN : 1884-1791
Print ISSN : 1340-4903
ISSN-L : 1340-4903
Volume 28 , Issue 6
Showing 1-8 articles out of 8 articles from the selected issue
  • Katsuyuki MORIWAKI, Kyoko OHSHITA, Yasuo TSUTSUMI
    2021 Volume 28 Issue 6 Pages 91-99
    Published: June 25, 2021
    Released: June 25, 2021
    JOURNALS FREE ACCESS FULL-TEXT HTML

    On January 1st, 2022, International Classification of Diseases 11th revision (ICD-11), which for the first time added codes for the classification of chronic pain, will come into effect. This systematic classification of chronic pain was developed by the task force of the International Association for the Study of Pain (IASP), where chronic pain is defined as pain that persists or recurs for more than three months and divided into chronic primary pain and chronic secondary pain. The latter chronic secondary pain is pain caused by underlying illness or tissue damage and is further divided into six categories according to the mechanisms and body parts. The IASP classification reflects pain concepts based on recent new scientific findings on chronic pain and is expected to bring about significant advances in the management of chronic pain. ICD-11 browser in the website of World Health Organization is also useful as a clinical tool for diagnosing chronic pain.

  • Mikito KAWAMATA, Takuma SASAKI, Mitsuhiro ISHIDA, Toru ISHIBASHI, Hide ...
    2021 Volume 28 Issue 6 Pages 100-108
    Published: June 25, 2021
    Released: June 25, 2021
    JOURNALS FREE ACCESS FULL-TEXT HTML

    Objective: The study evaluated the efficacy, safety, and pharmacokinetics before and after a switchover from oxycodone hydrochloride controlled-release tablet to S-8117OTR in patients with moderate to severe chronic pain. Method: This study was a multicenter, non-randomized, open-label design that enrolled patients with moderate to severe non-cancerous chronic pain at 27 study sites nationwide. The primary endpoint was defined as the percentage of patients that maintained pain control during the switchover treatment phase. Results: A total of 81 patients were enrolled. Among them, 61 patients entered the switchover phase, and 44 patients completed the study. The primary endpoint, the percentage of patients that maintained pain control [95% confidence interval] was 80.3% [68.2, 89.4]. Treatment related adverse events reported ≧5% were constipation, nausea, somnolence, and vomiting. None of the patients were considered as drug dependence. Conclusion: There was no significant difference in efficacy, safety and pharmacokinetics before and after switching from oxycodone hydrochloride controlled-release tablet to S-8117OTR.

feedback
Top